Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPHC.L Regulatory News (PHC)

  • There is currently no data for PHC

Trading Statement

22 Jan 2009 07:00

RNS Number : 0678M
Plant Health Care PLC
22 January 2009
 



For release: 7am 22 January 2009

 

PLANT HEALTH CARE PLC

("Plant Health Care" or "the Company")

Trading Update

Plant Health Care (AIM: PHC.L), a leading provider of natural products for plants and soil, provides the following post year end update for 2008, ahead of the announcement of its Preliminary Results which is expected by early April 2009.

The Company continues to trade well and, with further sales growth and the benefit of the initial order from Monsanto Company ("Monsanto") in the second half of the year, is expecting to report a result (before share based payments) in line with market expectations. 

The cash position at 31 December was $7.3 million, a marked improvement on the $6.2 million previously estimated, as a result of tight cash management.

In December 2008, Plant Health Care announced an agreement with Monsanto for the commercialisation of its harpin technology as a seed treatment in Monsanto's major row crops (corn, cotton, soybeans and canola) and selected vegetables. As stated above, a significant order has already been received and the board believes the Monsanto agreement will make a material contribution to the Company's future revenue and profits. It is expected that in future years the Monsanto payments will mainly fall into the second half of the year and this will accentuate the current trading pattern which sees stronger revenues in the second half, reflecting the timing of orders to suit the growing seasons.

Plant Health Care announced in December the termination of its agreement with Bayer CropScience for the development of Myconate. However, the Company is continuing its discussions with several large multinational seed companies and, supported by further strong test results for this product, expects to conclude an agreement with another party during 2009.

The Board considers that 2008 has seen significant progress for Plant Health Care, in particular the transformational agreement with Monsanto, and, despite challenging conditions in the wider economy, believes that the long term drivers of Plant Health Care's core markets remain very strong.

-Ends-

For further information please contact:

Plant Health Care plc

John Brady, Chief Executive Officer

Tel: +1-603-525-3702

jabrady@planthealthcare.com

 

Evolution Securities

Tavistock Communications 

Tim Worlledge / Tim Redfern

Jeremy Carey/Matt Ridsdale

Tel: +44-20-7071-4300 

Tel: +44-20-7920-3150

tim.worlledge@evosecuties.com/

tim.redfern@evosecuties.com

jcarey@tavistock.co.uk / mridsdale@tavistock.co.uk

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTIIFSRLVIFFIA
Date   Source Headline
27th Jan 20214:41 pmRNSSecond Price Monitoring Extn
27th Jan 20214:36 pmRNSPrice Monitoring Extension
25th Jan 20217:00 amRNSTrading Statement
11th Jan 20217:00 amRNSNotice of Trading Statement/Investor Presentation
5th Jan 20213:37 pmRNSBrazil approves PHC279 to Control Soybean Rust
11th Dec 20207:00 amRNSInvestor Presentation
9th Nov 20207:00 amRNSPlant Health Care and Wilbur-Ellis sign Agreement
7th Oct 20207:00 amRNSGrant of Options
6th Oct 20207:00 amRNSNew US PREtec Patents Issued
2nd Oct 20205:48 pmRNSSignificant Shareholder
25th Sep 20207:00 amRNSInvestor Presentation
23rd Sep 20207:00 amRNSInvestor Presentation
15th Sep 20207:00 amRNSInterim Report 30 June 2020
29th Jul 20207:00 amRNSTrading Statement
26th Jun 20204:41 pmRNSSecond Price Monitoring Extn
26th Jun 20204:36 pmRNSPrice Monitoring Extension
25th Jun 20207:00 amRNSGrant of Options
18th Jun 20204:41 pmRNSSecond Price Monitoring Extn
18th Jun 20204:36 pmRNSPrice Monitoring Extension
16th Jun 20207:00 amRNSPHC398 Approved by US EPA: PHC279 submitted to EPA
9th Jun 20207:00 amRNSGrant of options
2nd Jun 202011:13 amRNSResult of AGM
29th May 20207:00 amRNSHolding(s) in Company
27th May 20207:00 amRNSUpdate on PHC279 2019 Field Trials
6th May 20205:12 pmRNSAnnual Report & Accounts and AGM Notice Published
1st May 20203:21 pmRNSDirector/PDMR Shareholding
24th Apr 20207:00 amRNSResults for the year ended 31 December 2019
25th Mar 20207:00 amRNSHolding(s) in Company
23rd Mar 20203:45 pmRNSHolding(s) in Company
19th Mar 20203:09 pmRNSHolding(s) in Company
16th Mar 202011:53 amRNSResults of General Meeting
11th Mar 20207:00 amRNSPHC279 Submitted for Regulatory Approval in Brazil
24th Feb 20209:18 amRNSResults of Placing and Subscription
24th Feb 20207:00 amRNSProposed Placing and Subscription
19th Feb 20207:00 amRNSBlock listing Interim Review
5th Feb 20207:00 amRNSEmploy California Registration
23rd Jan 20207:00 amRNSFirst US patent issues for PREtec peptide products
9th Jan 20207:00 amRNSBrazil Update
20th Dec 20197:00 amRNSHolding(s) in Company
19th Dec 20197:00 amRNSTrading Update
3rd Dec 20196:35 pmRNSHolding(s) in Company
22nd Nov 20192:11 pmRNSHolding(s) in Company
15th Nov 20193:42 pmRNSHolding(s) in Company
15th Nov 20193:36 pmRNSHolding(s) in Company
14th Nov 20193:36 pmRNSHolding(s) in Company
14th Nov 20197:00 amRNSHolding(s) in Company
13th Nov 20194:40 pmRNSHolding(s) in Company
13th Nov 20194:08 pmRNSHolding(s) in Company
13th Nov 20193:59 pmRNSHolding(s) in Company
13th Nov 20193:42 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.